Ajanta Pharma, a Rs.450 crore plus Mumbai based pharma major, has posted satisfactory performance during the second quarter ended September 2011. Its net profit improved by 17.9 per cent to Rs.11.85 crore from Rs.10.05 crore and its net sales increased by 20.1 per cent to Rs.135.13 crore from Rs.112.51 crore in the corresponding period of last year. EBDITA also moved up by 10 per cent to Rs.23.46 crore.


For the first half ended September 2011, Ajanta's net sales jumped by 24.5 per cent to Rs.262.44 crore from Rs.210.79 crore in similar period of last year. Its net profit touched to Rs.24.38 crore from Rs.17.03 crore, representing a growth of 43.2 per cent.


Yogesh Agrawal, managing director, said, “We continue to work for our future growth, while achieving consistent performance during the current period. We are happy to inform you that we have received one more product (ANDA) approval from US during the quarter. With this approval, Ajanta Pharma has two approved products for US. We have filed three more products for approval in US.”


“Our Q2 performance has been satisfactory. It could have been better but for the adverse impact of sudden currency movement. We are confident that we will improve the performance further in the coming quarters,” he added.